Malignant Esophageal Neoplasm — Trials

Malignant Esophageal Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 518
Recruiting: 302
Ph III recruiting: 41
Growth YoY: +2.4%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 28.5%
Trials / 1,000 deaths: 32.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 151–200 of 1,926 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05713838	Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical Surgery	active not recruiting	Phase 2	32	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER	1	Aug 7, 2026	clinicaltrials
NCT07751055	Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal Cancer(NEOCRTE2601)	recruiting	Phase 2	51	Sun Yat-sen University